Published August 31, 2026
Every morning our data team scans the GLP-1 wire for stories that will actually matter to people who eat on these medications. This one — 'Semaglutide now has four prices at once: $1,350 to $50', from a news source on 2026-09-02 — made the cut, and the analysis below connects it to the food data rather than repeating the press release.
This story is on our radar. We cover GLP-1 news by checking the source and translating only the food-relevant part into the site's usual terms — protein, fiber and fat. Where a story makes food claims, the USDA data is the referee.
Strip the headline off almost any GLP-1 story and the same three variables sit underneath: protein for muscle, fat as the nausea trigger, fiber and water for regularity. Those are the exact axes this site scores every food on, which is why a study headline and a scored food usually agree.
Whatever the angle of the story — heart, kidney, muscle, side effects — the practical food response is remarkably consistent. That consistency is deliberate: the verdict labels are a fixed reference, so a reader does not need the news to know what to eat on any given day.
The line is deliberate: food data describes foods, and clinicians manage treatments. If a story raises a question about your own medication, that question belongs with your healthcare provider, not with the data on this site — and this post keeps to its side of the line.
We cover a story when it is recent, sourced, and relevant to people who eat on a GLP-1. Unlinked rumors never make it to a page, because the site's whole method is traceability — applied to news the same way it is applied to food values.
The food-side takeaway from this story: traceable sources and food data.
Keep the plate pattern: protein first, vegetables second, and the heavy stuff in small servings — the site's verdict labels are the shorthand.
If the story touches side effects, the food fixes are low-fat choices for nausea and fiber-plus-water for constipation. If it touches outcomes, the food answer is the same plate, consistently.
News changes, data doesn't: any headline question about your own dose or symptoms is a conversation for your healthcare provider.
The medication works over days; the food pattern works over the week. Judging food weekly matches how both actually behave. The week is long enough to show the trend and short enough to act on it.
The plate that works at home is the plate that works in a restaurant and at a holiday table: protein first, vegetables to fill, a small quarter for the indulgence, sauce separate. The structure does not depend on the occasion — the food names change, the scoring behind them does not, and the linked pages show the values. The structure is what survives the week; the foods on it can rotate.
The pattern fixes this site can stand behind are the food-side ones: smaller portions, plainer preparation, and moving heavy foods earlier in the day. Those cover most of the discomfort the data can explain. What a scored entry cannot do is diagnose, adjust a dose, or weigh one treatment against another — when symptoms persist past the food fixes, that is exactly the information your healthcare provider needs. The line is simple to state and hard to beat: food data here, medicine with your clinician.
Most GLP-1 headlines leave the plate unchanged: protein first, small portions, fiber and water are the constants. What the story can do is point at one nutrient worth extra attention — muscle news leads back to protein, side-effect news leads back to fat and fiber — and those are the variables this site scores on. Anything about your own dose or treatment stays with your clinician.
A single story is not a reason to change what you eat. The verdicts rest on USDA values and published guideline frameworks, and those do not move with the news cycle — a study may refine the framework eventually, but one headline does not change the per-100g numbers. The stable response is the stable plate: protein first, vegetables, small servings, water.
Look for three things: a named source, a recent date, and a study or agency standing behind the claim. Journals like JAMA and NEJM and agencies like the FDA clear the bar; link-less headlines do not. Be skeptical of any story that overstates a single trial. This post names and links its source — the same standard we use for everything on the site.
Weekly is a good rhythm. The plate guidance shifts slowly, so there is no advantage to reading every headline the day it lands; the stable verdicts here cover the food side regardless. If a story does affect your treatment, the right next step is a conversation with your provider, not another article.
Source: a news source · 2026-09-02. Source linked, food angle analyzed, clinical questions handed to your clinician — that is the whole treatment here.
Prepared by the data editorial team from USDA FoodData Central and the published guideline frameworks named above, this page is an information resource — not a treatment plan. Your healthcare provider is the person for dose, symptom and medication questions, and this post is explicit about that boundary. That is the food column; the clinical column stays with your provider.
Every morning our data team scans the GLP-1 wire for stories that will actually matter to people who eat on th
Next-gen GLP-1s outperform Mounjaro: 38-trial analysis puts…We follow the GLP-1 news the way we follow food data: note the source, check the claims, and write only what c
Semaglutide and alcohol: three human trials, three different…News coverage of GLP-1s moves fast, and our job is the slow part: connect the headline to the food data and ke